Latest / Vanguards of Healthcare by Bloomberg Intelligence
Tandem Diabetes’ Pump Portfolio Has Rubber Hitting the Floor
“If you look at the tubeless market, you know, we're seeing growth rates in excess of 25% annually,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about the growth opportunities in insulin pumps. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s pending launch of Mobi Tubless, an insulin pump designed to wear on the body for discretion and the AI-powered Control-IQ Plus algorithm for simplicity. The conversation also touches on the company’s pay-as-you-go…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.